Helius Medical Technologies Inc (HSDT)
4.56
+0.12
(+2.70%)
USD |
NASDAQ |
Apr 26, 16:00
4.56
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 4.046M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -53.14% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 4.436 |
Price to Book Value | 1.722 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.97% |
Profile
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise. |
URL | https://www.heliusmedical.com |
Investor Relations URL | N/A |
HQ State/Province | Pennsylvania |
Sector | Health Care |
Industry | Health Care Equipment & Supplies |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Mar. 28, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise. |
URL | https://www.heliusmedical.com |
Investor Relations URL | N/A |
HQ State/Province | Pennsylvania |
Sector | Health Care |
Industry | Health Care Equipment & Supplies |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Mar. 28, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |